- Home
- TACT vs INKT Comparison
TACT vs INKT Comparison
Compare TACT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- INKT
- Stock Information
- Founded
- TACT 1996
- INKT 2017
- Country
- TACT United States
- INKT United States
- Employees
- TACT N/A
- INKT N/A
- Industry
- TACT Computer peripheral equipment
- INKT Medicinal Chemicals and Botanical Products
- Sector
- TACT Technology
- INKT Health Care
- Exchange
- TACT Nasdaq
- INKT Nasdaq
- Market Cap
- TACT 35.7M
- INKT 28.8M
- IPO Year
- TACT 1996
- INKT 2021
- Fundamental
- Price
- TACT $3.58
- INKT $21.07
- Analyst Decision
- TACT Strong Buy
- INKT Hold
- Analyst Count
- TACT 1
- INKT 3
- Target Price
- TACT $5.00
- INKT $37.50
- AVG Volume (30 Days)
- TACT 14.7K
- INKT 2.9M
- Earning Date
- TACT 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- TACT N/A
- INKT N/A
- EPS Growth
- TACT N/A
- INKT N/A
- EPS
- TACT N/A
- INKT N/A
- Revenue
- TACT $45,750,000.00
- INKT N/A
- Revenue This Year
- TACT $17.09
- INKT N/A
- Revenue Next Year
- TACT N/A
- INKT N/A
- P/E Ratio
- TACT N/A
- INKT N/A
- Revenue Growth
- TACT N/A
- INKT N/A
- 52 Week Low
- TACT $3.12
- INKT $4.56
- 52 Week High
- TACT $5.11
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- TACT 45.65
- INKT 55.06
- Support Level
- TACT $3.59
- INKT $23.11
- Resistance Level
- TACT $4.00
- INKT $76.00
- Average True Range (ATR)
- TACT 0.17
- INKT 7.20
- MACD
- TACT -0.01
- INKT 1.20
- Stochastic Oscillator
- TACT 18.52
- INKT 23.55
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.